Core Insights - Regeneron reported $3.75 billion in revenue for Q3 2025, a year-over-year increase of 0.9%, with an EPS of $11.83 compared to $12.46 a year ago, exceeding the Zacks Consensus Estimate of $3.6 billion by 4.38% and delivering an EPS surprise of 25.32% [1] Revenue Performance - Praluent (alirocumab) generated $67.7 million in the US, surpassing the $57.39 million estimate, reflecting a 28% year-over-year increase [4] - Eylea (Aflibercept) in the US reported $1.11 billion, slightly above the $1.09 billion estimate, but a decrease of 27.7% year-over-year [4] - Libtayo generated $146.1 million in ROW, exceeding the $123.89 million estimate, marking a 55.3% year-over-year increase [4] - Total net product sales were $1.59 billion, slightly above the $1.57 billion estimate, but down 18.4% year-over-year [4] - Collaboration revenues totaled $1.97 billion, exceeding the $1.85 billion estimate, with an 18.6% year-over-year increase [4] - Other revenue reached $198.2 million, significantly above the $131.84 million estimate, representing a 73.6% year-over-year increase [4] Stock Performance - Regeneron's shares returned 4.4% over the past month, outperforming the Zacks S&P 500 composite's 3.6% change, with a current Zacks Rank of 3 (Hold), indicating potential performance in line with the broader market [3]